10-Q: Ekso Bionics Reports Second Quarter 2024 Results, Focuses on Growth and Cost Management

Ekso Bionics' second quarter 2024 results show a slight revenue decrease but improved gross margins and reduced operating expenses, alongside ongoing efforts to secure funding and navigate market challenges.

Summary

• Ekso Bionics reported a net loss of $2.4 million for the three months ended June 30, 2024, and a net loss of $5.8 million for the six months ended June 30, 2024.
• Revenue for the quarter was $4.95 million, a 5% increase compared to the same period in 2023, while revenue for the six months was $8.7 million, a 1% decrease compared to the same period in 2023.
• The company's gross profit margin improved to 53% for both the three and six months ended June 30, 2024, compared to 48% for the same periods in 2023.
• Operating expenses decreased by 24% for the three months and 22% for the six months ended June 30, 2024, due to lower sales and marketing, research and development, and general and administrative costs.
• The company used $6.1 million in operating activities during the first six months of 2024 and had $5.9 million in cash and restricted cash as of June 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional financing.

Sentiment

Score: 4

Explanation: The document shows some positive trends in gross margin and expense reduction, but the substantial doubt about the company's ability to continue as a going concern and the ongoing losses significantly weigh down the sentiment.

Positives

• The company achieved a 5% increase in revenue for the second quarter of 2024.
• Gross profit margins improved significantly to 53% for both the three and six month periods.
• Operating expenses were reduced by 24% in Q2 and 22% in the first six months of 2024.
• The company successfully raised $3.9 million through a registered direct offering in January 2024.
• CMS approval for Medicare reimbursement of the Ekso Indego Personal device at $91,031.93 per unit is a significant positive development.

Negatives

• The company experienced a slight decrease in revenue for the first six months of 2024 compared to the same period in 2023.
• The company continues to operate at a loss, with a net loss of $2.4 million for Q2 2024 and $5.8 million for the first six months of 2024.
• The company used $6.1 million in operating activities during the first six months of 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional financing.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company faces competition in the medical device and industrial robotics markets.
• The company's revenue is dependent on market demand for its exoskeleton products, which is influenced by various factors including economic conditions and reimbursement levels.
• The company's business plan depends on sales of the Ekso Indego Personal product to individuals covered by Medicare or Medicaid, and any changes to reimbursement policies could impact sales.
• The company must obtain regulatory approvals in the EU, which could be costly and time-consuming.
• Future issuances of equity securities could dilute existing shareholders and depress the market price of the company's common stock.

Future Outlook

Management intends to raise funds through one or more financings and is exploring strategic initiatives to fuel growth and long-term value. The company expects to recognize approximately $1.2 million of deferred revenue during the remainder of 2024, $1.4 million in 2025, and $1.4 million thereafter. The company also has a non-cancellable backlog of $2.9 million expected to be recognized between 2024 and 2026.

Management Comments

• Management intends to raise funds through one or more financings.
• Management plans include delaying or abandoning certain product development projects, cost reduction efforts for our products, and refocused sales efforts to accelerate revenue growth above historical results if sufficient financing is not secured.
• Management believes that the company's Personal Health business line has the potential for a higher growth rate than its Enterprise Health business line.

Industry Context

The company operates in the competitive medical device and industrial robotics markets, where demand is influenced by factors such as awareness of robotic exoskeleton rehabilitation, adoption of safety practices, and reimbursement levels. The recent CMS approval for the Ekso Indego Personal device is a positive development that could drive increased demand. The company's performance is also affected by global economic conditions and currency fluctuations.

Comparison to Industry Standards

• The company's gross margin of 53% is a positive sign, but it is difficult to compare directly to industry standards without more specific data on comparable companies in the exoskeleton market.
• The company's operating expense reductions are a positive step, but further analysis is needed to determine if these reductions are sustainable and sufficient to achieve profitability.
• The company's reliance on external financing is a common challenge for early-stage medical device companies, but the uncertainty around future funding raises concerns.
• The company's focus on securing reimbursement for its products is critical for long-term success, and the CMS approval for the Ekso Indego Personal is a significant milestone.
• The company's performance should be compared to other companies in the rehabilitation robotics space, such as ReWalk Robotics and Cyberdyne, to assess its relative position.

Related Party Transactions

• The company made payments to settle a consulting agreement with an entity affiliated with a board member.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity issuances and the potential for a decline in share price.
• Employees may be affected by potential cost reduction efforts and changes in product development projects.
• Customers may be impacted by the company's ability to continue operations and provide ongoing support for its products.
• Suppliers may be affected by the company's financial stability and ability to meet its purchase obligations.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company intends to raise funds through one or more financings.
• The company will continue to seek insurance coverage beyond CMS.
• The company will continue to seek additional indications of use for its products.
• The company will continue to pursue CE certification for its products in the EU.

Key Dates

Keywords

exoskeleton, medical devices, rehabilitation, EksoHealth, EksoWorks, Medicare, CMS, financing, revenue, gross margin, operating expenses, net loss, warrants, EU MDR